BD’s third quarter results for 2013 show growth

BD has published its financial report for the third quarter of the 2013 business year, during which it generated quarterly revenues of $2.05 billion (1.35 billion pounds).

This represented a year-on-year increase of 3.6 percent, with strong sales of its medical and diagnostics products helping to offset the relative difficulties experienced by its biosciences division.

For the full year, the company has reaffirmed its previously communicated guidance, with revenue growth expected to approach five percent on a currency-neutral basis, towards the upper end of its range.

Vincent Forlenza, chairman, chief executive officer and president of BD, said: "Our solid results against the backdrop of a challenging environment demonstrate that we are executing on our strategy and delivering on our commitments."

This comes after the firm announced a new alliance with the College of American Pathologists earlier this week that will see it helping to provide solutions to advance laboratory quality for improved patient outcomes in China and India.